company background image

Global Blood Therapeutics NasdaqGS:GBT Stock Report

Last Price


Market Cap







05 Jul, 2022


Company Financials +
GBT fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance0/6
Financial Health4/6

GBT Stock Overview

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD).

Global Blood Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Global Blood Therapeutics
Historical stock prices
Current Share PriceUS$33.28
52 Week HighUS$40.69
52 Week LowUS$21.65
1 Month Change27.46%
3 Month Change-9.74%
1 Year Change-0.48%
3 Year Change-40.39%
5 Year Change18.43%
Change since IPO-22.80%

Recent News & Updates

Jun 29

GBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease

Global Blood Therapeutics (NASDAQ:GBT) said on Wednesday it had begun the Phase 2 portion of a Phase 2/3 trial of its drug candidate GBT601, to treat sickle cell disease. The drug, GBT601, is a sickle hemoglobin (HbS) polymerization inhibitor and works by achieving higher hemoglobin levels and occupancy at a lower dose. "It has the potential to improve on the clinical results achieved with Oxbryta at a lower daily dose," said Kim Smith-Whitley, head of research and development of GBT. The company's drug, Oxbryta, is FDA approved to treat sickle cell disease. The company expects initial data from the trial as well as data from the continuation of GBT601 Phase 1 study to be available before the end of the year. The mid-stage portion of the study will enroll up to 60 patients who are 18 to 65 years of age.

Jun 21

Global Blood Therapeutics: Powerhouse Of The Future

In the latest 1Q2022 earnings report, the lead medicine Oxbryta continues to generate highly aggressive growth. You can expect even stronger growth due to the recent Oxbryta launch for kids in the EU. There are also adult campaigns in other countries outside of the USA. Two promising molecules (GBT601 and inclacumab) would power long-term upsides.

Shareholder Returns

GBTUS BiotechsUS Market

Return vs Industry: GBT exceeded the US Biotechs industry which returned -25.1% over the past year.

Return vs Market: GBT exceeded the US Market which returned -19.1% over the past year.

Price Volatility

Is GBT's price volatile compared to industry and market?
GBT volatility
GBT Average Weekly Movement10.5%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.3%

Stable Share Price: GBT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: GBT's weekly volatility (11%) has been stable over the past year.

About the Company

2011457Ted Love

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.

Global Blood Therapeutics Fundamentals Summary

How do Global Blood Therapeutics's earnings and revenue compare to its market cap?
GBT fundamental statistics
Market CapUS$2.17b
Earnings (TTM)-US$309.58m
Revenue (TTM)US$210.87m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GBT income statement (TTM)
Cost of RevenueUS$3.79m
Gross ProfitUS$207.08m
Other ExpensesUS$516.66m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)-4.76
Gross Margin98.20%
Net Profit Margin-146.82%
Debt/Equity Ratio433.7%

How did GBT perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is GBT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GBT?

Other financial metrics that can be useful for relative valuation.

GBT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue10.3x
Enterprise Value/EBITDA-7.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does GBT's PS Ratio compare to its peers?

GBT PS Ratio vs Peers
The above table shows the PS ratio for GBT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average2081.1x
ALLO Allogene Therapeutics
BCRX BioCryst Pharmaceuticals
AUPH Aurinia Pharmaceuticals
RCUS Arcus Biosciences
GBT Global Blood Therapeutics

Price-To-Sales vs Peers: GBT is good value based on its Price-To-Sales Ratio (10.3x) compared to the peer average (2081.1x).

Price to Earnings Ratio vs Industry

How does GBT's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: GBT is good value based on its Price-To-Sales Ratio (10.3x) compared to the US Biotechs industry average (13.2x)

Price to Sales Ratio vs Fair Ratio

What is GBT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GBT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.3x
Fair PS Ratio15.3x

Price-To-Sales vs Fair Ratio: GBT is good value based on its Price-To-Sales Ratio (10.3x) compared to the estimated Fair Price-To-Sales Ratio (15.3x).

Share Price vs Fair Value

What is the Fair Price of GBT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GBT ($33.28) is trading below our estimate of fair value ($235.54)

Significantly Below Fair Value: GBT is trading below fair value by more than 20%.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GBT's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Global Blood Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?

Future Growth Score


Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GBT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GBT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GBT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GBT's revenue (32.1% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: GBT's revenue (32.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GBT is forecast to be unprofitable in 3 years.

Discover growth companies

Past Performance

How has Global Blood Therapeutics performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: GBT is currently unprofitable.

Growing Profit Margin: GBT is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: GBT is unprofitable, and losses have increased over the past 5 years at a rate of 21.7% per year.

Accelerating Growth: Unable to compare GBT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GBT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (98.2%).

Return on Equity

High ROE: GBT has a negative Return on Equity (-231.03%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Global Blood Therapeutics's financial position?

Financial Health Score


Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: GBT's short term assets ($675.6M) exceed its short term liabilities ($79.3M).

Long Term Liabilities: GBT's short term assets ($675.6M) exceed its long term liabilities ($656.2M).

Debt to Equity History and Analysis

Debt Level: GBT's net debt to equity ratio (20.7%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if GBT's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GBT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if GBT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Discover healthy companies


What is Global Blood Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate GBT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GBT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GBT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GBT's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as GBT has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Ted Love (63 yo)





Dr. Ted W. Love, M.D., serves as Independent Director at Royalty Pharma plc since July 30, 2020. He serves as Director of Seagen Inc. (formerly known as Seattle Genetics, Inc.). since August 2020. He serve...

CEO Compensation Analysis

Compensation vs Market: Ted's total compensation ($USD8.19M) is above average for companies of similar size in the US market ($USD5.53M).

Compensation vs Earnings: Ted's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: GBT's management team is seasoned and experienced (6.3 years average tenure).

Board Members

Experienced Board: GBT's board of directors are considered experienced (5.5 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.5%.

Top Shareholders

Company Information

Global Blood Therapeutics, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Global Blood Therapeutics, Inc.
  • Ticker: GBT
  • Exchange: NasdaqGS
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$2.166b
  • Shares outstanding: 65.10m
  • Website:

Number of Employees


  • Global Blood Therapeutics, Inc.
  • 181 Oyster Point Boulevard
  • South San Francisco
  • California
  • 94080
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/05 00:00
End of Day Share Price2022/07/05 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.